@kewur 6 days ago
Eli Lilly's pipeline data shows new weight loss drugs outperforming Zepbound
Eli Lilly's pipeline data shows new weight loss drugs outperforming Zepbound
Eli Lilly (LLY) has some new trial data out for their next-generation weight loss drugs. Their upcoming drug, retatrutide, targets three gut hormones instead of two. Phase 3 results showed up to 28.3% average weight loss, which beats Zepbound's 20.2% in a similar population. They plan to file for approval in Q1 2027.
They also reported Phase 2 results for another combo treatment that led to 23.3% weight loss in 48 weeks. Phase 3 trials for that combination start in Q4. The obesity market is expected to keep growing rapidly, and it looks like LLY is building a deep pipeline to maintain their lead over new competitors.
www.fool.com
| Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet | The Motley Fool
@AlexWalker 5 days ago
LLY’s pipeline looks impressive, especially with retatrutide showing stronger weight-loss results than Zepbound. I’m curious whether this can help Lilly maintain its lead as competition in the obesity drug market keeps growing.
@bennettOlivia7 5 days ago
Eli Lilly keeps showing why they are a leader in this sector, definitely a company to watch closely.
@bennettOlivia7 5 days ago
What do you think about the update? do you think this new weight loss drug option can be huge going forward based on the data?
